Hikma Pharmaceuticals Regulatory News (HIK)

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE UK CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE").

FOR IMMEDIATE RELEASE

4 February 2026

Statement regarding Hikma Pharmaceuticals Plc ("Hikma")

Brookfield Private Capital (DIFC) Limited, acting for and on behalf of funds managed and/or advised by its affiliates ("Brookfield") notes the recent press speculation and confirms that it does not intend to make an offer for Hikma.

This announcement is made by Brookfield in accordance with Rule 2.8 of the Code. As a result of this announcement Brookfield (and any person acting in concert with it) will, except with the consent of the UK Panel on Takeovers and Mergers (the "Panel"), be bound by the restrictions contained in Rule 2.8 of the Code.

Under Note 2 on Rule 2.8 of the Code, Brookfield reserves the right to set aside the restrictions in Rule 2.8 in the following circumstances: (i) with the agreement of the board of Hikma; (ii) if a third party announces a firm intention to make an offer for Hikma; (iii) if Hikma announces a Rule 9 waiver proposal (see Note 1 of the Notes on Dispensations from Rule 9) or a reverse takeover (as defined in the Code); or (iv) if there has been a material change of circumstances (as determined by the Panel).

Enquiries:

Brookfield

Marie Fuller +44 (0) 20 4557 4334

Important information

This announcement is not intended to, and does not, constitute, represent or form part of any offer, invitation or solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of any securities or the solicitation of any vote or approval in any jurisdiction whether pursuant to this announcement or otherwise.